Medicago Company Profile

15:36 EDT 18th March 2018 | BioPortfolio

Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The Company is committed to providing highly effective and competitive vaccines and therapeutic proteins based on its proprietary Virus-Like Particles (VLPs) and manufacturing technologies. Medicago is a worldwide leader in the development of VLP vaccines using a transient expression system which produces recombinant vaccine antigens in plants. This technology has potential to offer more potent vaccines with speed and cost advantages over competitive technologies, enabling the development of a vaccine for testing in approximately one month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic, and supply large volumes of vaccine antigens to the world market. Medicago also intends to expand development into other areas such as biosimilars and biodefense products where the benefits of our technologies can make a significant difference.

Medicago has reported positive results from its Phase II clinical trial with its avian flu H5 pandemic vaccine candidate. The vaccine was found to be safe, well tolerated and the results were among the most effective of the industry. Medicago also reported positive results from a U.S. Phase I human clinical trial with its seasonal influenza vaccine candidate. All vaccine doses were found to be safe, well tolerated and also induced a solid immune response that met the CHMP criteria, even with a single dose of 5 µg. Based on these results and subject to regulatory approval, Medicago intends to proceed with a U.S. Phase IIa trial for its seasonal quadrivalent vaccine with the recommended H1N1, H3N2 and two B influenza strains.

Medicago operates a 24,000-square-foot production facility located in the Technology Park in Quebec City, Canada. This facility includes a Biosafety level 2 greenhouse, an extraction and purification unit, and is cGMP compliant. Medicago is producing the preclinical and clinical lots required for the development of its influenza vaccines from its existing facility.

Medicago U.S.A., a wholly owned subsidiary of Medicago Inc., has completed the construction of its facility in Research Triangle Park (RTP), North Carolina. This Virus-Like-Particle plant-based vaccine facility includes a fully automated greenhouse and a state of the art extraction and purification unit. The 97,000-square-foot cGMP facility is targeted to produce 10 million doses of pandemic influenza vaccine per month. On an annual basis, the facility could have production capacity of 30 million doses of quadrivalent seasonal influenza vaccine or 120 million doses of pandemic influenza vaccine.


1020, route de l'Église, bureau 600
G1V 3V9


Phone: 418 658.9393
Fax: 418 658.6699

News Articles [7 Associated News Articles listed on BioPortfolio]

Low protease content in Medicago truncatula cell cultures facilitates recombinant protein production

Medicago truncatula is an established model for studying legume biology. More recently, it has also been exploited as a Molecular Farming platform for the production of recombinant proteins, with the ...

Medicago’s proteomic profile

Legumes have the unusual ability to make their own fertilizer. They do this by associating with nitrogen-fixing bacteria, which take nitrogen from the air and convert it to ammonia that can be used by...

This Company Is Testing A Flu Vaccine Made In Tobacco -- And Philip Morris Is On Board

As the FDA meets to plan next year's flu vaccine, companies like Medicago are testing innovative technologies designed to minimize the risk of another devastating outbreak.

Overexpression of AtEDT1 Gene Confers Drought Tolerance in Alfalfa

Alfalfa (Medicago sativa L.) is an important legume forage crop with great economic value. However, the growth of alfalfa is seriously affected by an inadequate supply of water, making drought the maj...

Medicago Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23082017] Prices from USD $250

SummaryMedicago Inc Medicago, a subsidiary of Mitsubishi Tanabe Pharma Corp is a biopharmaceutical company that develops and produces vaccines and antibodies. The company concentrates on the discovery...

20152023 World Bioactive Protein Market Research Report by Product Type, EndUser / Application and Regions / Countries [Report Updated: 24022018] Prices from USD $2800

SummaryThis report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and en...

Global Bioactive Protein Market Analysis 20122017 and Forecast 20182023 [Report Updated: 25012018] Prices from USD $2980

SummaryThe global Bioactive Protein market will reach xxx Million USD in 2017 and CAGR xx% 20112017. The report begins from overview of Industry Chain structure, and describes industry environment, th...

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Fast arthritis aid [Concept Laboratories, Inc.]


Painazin cp [Concept Laboratories, Inc.]


Moisturizing glucosamine brand [Concept Laboratories]


Mark. [Avon Products, Inc.]

Fresh juice e [SKINFOOD CO., LTD.]

Drug Facts

PubMed Articles [39 Associated PubMed Articles listed on BioPortfolio]

Genome-wide profiling of expression and biochemical functions of the Medicago glutathione S-transferase gene family.

Glutathione S-transferases are ubiquitous enzyme in plants, playing vital roles in several physiological and developmental processes. In this study we identified 73 GST genes from the genome of Medica...

Adapting the Lateral Root-Inducible System to Medicago truncatula.

Almost all legume plants have the capacity to form two types of root organs: lateral roots and nodules (that will host rhizobia that fix nitrogen). Transcriptomic analyses are useful to understand bot...

Lead phytoextraction from printed circuit computer boards by Lolium perenne L. and Medicago sativa L.

This work assessed the ability of Lolium perenne and Medicago sativa for extracting lead (Pb) from particulate printed circuit computer boards (PCB) mixed in sand with the following concentrations: 0....

CLE peptide tri-arabinosylation and peptide domain sequence composition are essential for SUNN-dependent autoregulation of nodulation in Medicago truncatula.

MtCLE12 and MtCLE13 encode CLAVATA3/EMBRYO-SURROUNDING REGION RELATED (CLE) peptides which regulate autoregulation of nodulation (AON) in Medicago through the shoot receptor, SUNN (SUPER NUMERIC NODUL...

Effect of short-term aluminum stress and mycorrhizal inoculation on nitric oxide metabolism in Medicago truncatula roots.

Aluminum (Al) toxicity can induce oxidative and nitrosative stress, which limits growth and yield of crop plants. Nevertheless, plant tolerance to stress may be improved by symbiotic associations incl...

Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]


Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The Company is committed to provi...

Medicago Inc.

More Information about "Medicago" on BioPortfolio

We have published hundreds of Medicago news stories on BioPortfolio along with dozens of Medicago Clinical Trials and PubMed Articles about Medicago for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Medicago Companies in our database. You can also find out about relevant Medicago Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Corporate Database Quicklinks

Searches Linking to this Company Record